| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514534000 | Z or Y radical contains a nitrogen atom | 84 |
| 20100010084 | HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 01-14-2010 |
| 20090156671 | DEUTERIUM-ENRICHED OXYBUTYNIN - The present application describes deuterium-enriched oxybutynin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 06-18-2009 |
| 20090124690 | Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins - The present invention relates to, in part, novel sulfate and bisphenol compounds useful for the recognition, attachment and growth of unwanted biologics on natural and manmade surfaces. Another aspect of the invention relates to combinatorial libraries for producing the same. Another aspect of the invention relates to pharmaceutical formulations comprising the same. | 05-14-2009 |
| 20120225940 | Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia - The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. | 09-06-2012 |
| 20090264525 | FLUOROSURFACTANTS - The present invention relates to fatty acid esters of polyols or sulfonated fatty acid esters or sulfonated fatty acid amides containing at least one group Y, where Y stands for CF | 10-22-2009 |
| 20110294881 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS - A method is provided for using α | 12-01-2011 |
| 20090036526 | CRYSTAL OF HYDROXYNOREPHEDRIN DERIVATIVE HYDROCHLORIDE 1/4 HYDRATE - The present invention provides ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride ¼ hydrate or a crystal thereof which can be determined by characteristic diffraction peaks of the powder X-ray diffraction, thermogravimetry-differential thermal analysis or the like, and obtained by manufacturing ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate by a specific method. | 02-05-2009 |
| 20120035261 | DEUTERIUM-ENRICHED SAXAGLIPTIN - The present application describes deuterium-enriched saxagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 02-09-2012 |
| 20090247628 | SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES - Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 10-01-2009 |
| 20090149534 | Crystalline modifications of (1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol - Crystalline modifications of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, pharmaceutical compositions which contain these modifications, and the use thereof to treat pain or other conditions. | 06-11-2009 |
| 20090163588 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS - This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. | 06-25-2009 |
| 20100216880 | TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS - The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics. | 08-26-2010 |
| 20090076144 | DEUTERIUM-ENRICHED BAZEDOXIFENE - The present application describes deuterium-enriched bazedoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
| 20110124726 | NOVEL CARBOXYLIC ACID DERIVATIVES - The present invention is concerned with novel arylalkyl carboxylic acid derivatives, more specifically, with acylates of arylalkyl carboxylic acids with naturally occurring, non-toxic hydroxyl, sulfhydryl, amino or imino compounds, and to compositions containing them. The compositions are preferably cosmetic preparations. | 05-26-2011 |
| 20090036527 | Therapeutic Application Of Leonurine In Treating Cardiomyopathy - The present invention provides methods for treating ischemic cardiomyopathy. In one embodiment, provided is a method of treating a disease characterized as ischemic cardiomyopathy, comprising administering to a subject suffering from said disease a pharmaceutical composition comprising therapeutically effective amount of synthesized Leonurine. The method induces at least one biochemical change to improve hypoxia myocardial cells survive rate, reduce LDH releasing from the ischemic myocardial cells, and reduce infarction area of cardiomyopathy in the subject. | 02-05-2009 |
| 20120016023 | Combination of Selected Opioids with Muscarine Antagonists for Treating Urinary Incontinence - Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided. | 01-19-2012 |
| 20100093855 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA - The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. | 04-15-2010 |
| 20100093854 | PROCESS FOR THE PREPARATION OF (-)-(4-CHLORO-PHENYL)-(3-TRIFLUOROMETHYL-PHENOXY)-ACETIC ACID 2-ACETYLAMINO-ETHYL ESTER - The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate. | 04-15-2010 |
| 20090018190 | Compositions and Methods for Transdermal Oxybutynin Therapy - The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel. | 01-15-2009 |
| 20100168232 | Oligomer-Anticholinergic Agent Conjugates - The invention provides anticholinergic agents that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the anticholinergic agent not attached to the water-soluble oligomer. | 07-01-2010 |
| 20130150441 | Oligomer-Anticholinergic Agent Conjugates - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the small molecule drug not attached to the water-soluble oligomer. | 06-13-2013 |
| 514535000 | The nitrogen of the Z radical is directly bonded to a benzene ring which is directly bonded to the C(=O) group | 27 |
| 20080306149 | Use for a Composition Comprising Chloroprocaine Hcl, a New Composition Comprising Chloroprocaine Hcl and a Method for Its Manufacture - The present invention concerns a new use for a composition comprising chloroprocaine HCl, and in particular its use for the manufacture of a drug for intrathecal narcosis. The present invention also concerns a new composition comprising chloroprocaine HCl, being particularly suited to this new use, as well as a new method for manufacturing said composition. | 12-11-2008 |
| 20090253786 | Synthesis, anti-allergic, anti-asthmatic and anti-inflammatory activities of CEE-1 and CEE-2 - “Enhydrazone esters of formula (I): wherein R is methyl or ethyl group have been synthesized. The compounds of formula (I) are potent inhibitors of degranulation of both mast cells and eosinophils. These compounds also suppress cytokines generation by leukocytes. These biological activities are relevant to the prevention and/or treatment of asthma, allergies and inflammatory diseases. It is known to the art that inhibitors of mast cell degranulation such as cromolyn sodium and nedocromil sodium are used in the treatment of asthma and other allergic diseases. Inhibitors of cytokine generation, such as steroids, are also useful in the prevention and treatment of inflammatory diseases as well as asthma and allergies”. | 10-08-2009 |
| 20100267827 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS - The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder. | 10-21-2010 |
| 20090281181 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases - The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease. | 11-12-2009 |
| 20090286876 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS - The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof. | 11-19-2009 |
| 20110269834 | COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES - Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS). | 11-03-2011 |
| 20090253787 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION - The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals. | 10-08-2009 |
| 20110060043 | INHIBITORS OF CELL PROLIFERATION AND USES THEREOF - The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation. | 03-10-2011 |
| 20110086913 | METHODS FOR TREATING MYOFASCIAL, MUSCLE, AND/OR BACK PAIN - The present disclosure is drawn to methods for treating myofascial pain, muscle pain, back pain, or combinations of these pains. Specifically, a method for treating myofascial pain, muscle pain, back pain, or combinations thereof includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for a period of time of at least 30 minutes. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation which includes at least one local anesthetic. The heating component can be capable of heating the skin surface to a temperature of 36° C. to 42° C. | 04-14-2011 |
| 20110124727 | Oxybuprocaine-Containing Analgesic/Antipruritic External Preparation - An analgesic/antipruritic external preparation that includes a local anesthetic, has fewer side effects, and has an excellent therapeutic effect on pain and itching of the skin is provided. The analgesic/antipruritic external preparation includes oxybuprocaine or a pharmaceutically acceptable salt thereof as an active ingredient, and the oxybuprocaine or a pharmaceutically acceptable salt thereof is contained in an amount of 0.1 to 60 wt %, more preferably 1 to 40 wt %, and most preferably 5 to 30 wt %. The analgesic/antipruritic external preparation has a dosage form as an external preparation wherein the dosage form is an ointment, a solution, a suspension, an emulsion, a lotion, a cataplasm, a tape, an aerosol, or a powder for external use. | 05-26-2011 |
| 20100063146 | METHOD FOR TREATING DISORDERS RELATED TO COMPLEMENT ACTIVATION - A method for treating or preventing a complement activated T-cell mediated disorder in a subject includes administering a therapeutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes at least one amidine compound or pharmaceutically acceptable salt. | 03-11-2010 |
| 20120004303 | METHOD OF DISPENSING A TEETHING GEL WITH A METERED DOSE APPLICATOR - A method of treating periodontal pain from teething that uses an applicator to dispense a medicament composition, wherein said applicator dispenses a metered dose of a therapeutic amount of said medicament composition. | 01-05-2012 |
| 20100010085 | Compositions and Methods for Treating Jellyfish Stings - Methods and compositions for treating skin conditions, in particular jellyfish stings, are provided. | 01-14-2010 |
| 20120283326 | ANTHRANILIC ACID DERIVATIVES - Compounds of formula (I) are provided, wherein X is CH═CH, CH | 11-08-2012 |
| 20120101157 | 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof - Disclosed are 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives and manufactures thereof. The 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives are presented by formula (I): | 04-26-2012 |
| 20080255232 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation - Compounds useful in the treatment of disorders characterized by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are those having the Formula (I) as reported below, where the radicals have the meaning indicated in the description. | 10-16-2008 |
| 20080227859 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same - The present invention relates to a tetrafluorobenzyl derivative and a pharmaceutical composition for prevention and treatment of acute and chronic neurodegenerative disease in central nervous system and ophthalmic diseases containing the same. The tetrafluorobenzyl derivative of the present invention can effectively be used to prevent and treat chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, degenerative brain disease such as epilepsy and ischemic brain disease such as stroke. | 09-18-2008 |
| 20130096191 | Benzonatate Compositions and Methods of Use - Oral dosage forms of benzonatate useful for anti-tussive and anti-tussive/combination applications. | 04-18-2013 |
| 514536000 | With an agent to enhance topical absorption or with a stabilizing agent | 4 |
| 20130079404 | TOPICAL FORMULATION - It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. | 03-28-2013 |
| 20100240749 | ANESTHETIC SPRAY COMPOSITION - An anesthetic spray composition suitable for application to the back of the throat comprising a topical anesthetic and a mucoadhesive polymer. | 09-23-2010 |
| 20080214664 | ANESTHETIC SPRAY COMPOSITION - An anesthetic spray composition suitable for application to the back of the throat comprising a topical anesthetic and a mucoadhesive polymer. | 09-04-2008 |
| 20130131166 | BIOADHESIVE COMPOSITIONS FOR EPITHELIAL DRUG DELIVERY - Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time. | 05-23-2013 |
| 514537000 | With an additional active ingredient | 5 |
| 20120065259 | HEAT ASSISTED LIDOCAINE AND TETRACAINE FOR TRANSDERMAL ANALGESIA - The present disclosure is drawn to methods for treating various types of pain, including pain associated nerve entrapment, neuroma, headaches, connective tissue, arthritis, injury, and/or overuse. Specifically, the method includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for an application period of at least 30 minutes. Following the application period the analgesic system can be removed and the subject being treated continues to experience reduction of pain for a period of 2 to 10, or even 4 to 12 hours after removal of the analgesic system. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation. | 03-15-2012 |
| 20110112189 | METHODS OF TREATING PAINS ASSOCIATED WITH NEUROMA, NERVE ENTRAPMENT, AND OTHER CONDITIONS - The present disclosure is drawn to methods for treating nerve entrapment pain; neuroma pain; headache associated with neuralgia; connective tissue pain such as iliotibial band pain, blood vessel pain, tendinopathy pain, medial tibial stress syndrome pain, bursitis, etc.; arthritis pain such as osteoarthritis pain or rheumatoid arthritis pain; pain associated with injury such as fracture, severance, break, sprain, strain, tear, point pain, (e.g., trigger point pain or hit point pain), focal pain, or bruise; or combinations of these pains. Specifically, a method for treating various types of pain includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for a period of time of at least 30 minutes. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation which includes at least one local anesthetic. The heating component can be capable of heating the skin surface to a temperature of 36° C. to 42° C. | 05-12-2011 |
| 20120022158 | SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL - Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site. | 01-26-2012 |
| 20120101158 | Surface Anesthetic Agent - Provided is an anesthetic agent which can exhibit an anesthetic effect rapidly when adhered on mucosal membranes, the skin or the like by means of application or the like in local anesthesia, particularly surface anesthesia. Prepared are: a fast-acting surface anesthetic agent containing lidocaine and ethyl paraaminobenzoate at a specific ratio; and a super fast-acting surface anesthetic agent containing lidocaine, ethyl paraaminobenzoate and adrenaline at a specific ratio. | 04-26-2012 |
| 20130150442 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCERS - The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided. | 06-13-2013 |
| 514538000 | Nitrogen bonded to carbon in Z moiety | 36 |
| 20100076079 | Pharmaceutical Compositions Of Short-Acting Sedative Hypnotic Agent - The invention provides pharmaceutical compositions comprising a phenylacetic acid ester compound useful for inducing or maintaining general anesthesia or sedation in mammals, methods for preparing such compositions, and methods for inducing or maintaining anesthesia or sedation using such compositions. | 03-25-2010 |
| 20080293810 | MULTI-DOSE CONCENTRATE ESMOLOL WITH BENZYL ALCOHOL - Disclosed are concentrate esmolol injection essentially free from other related esters of esmolol and diluted esmolol compositions. The concentrate esmolol formulation includes from about 25-1000 mg/ml of esmolol and about 1-25% w/v of benzyl alcohol and the combination thereof. The compositions can also be used as multi-dose compositions. The present invention also discloses diluted, ready-to-use compositions of esmolol prepared by dilution of the present invention concentrates. Also disclosed are methods of making and using the ready-to-use compositions of the present invention. | 11-27-2008 |
| 20100004332 | Levodopa Prodrugs, and Compositions and Uses Thereof - Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed. | 01-07-2010 |
| 20090326067 | Levodopa Prodrug Mesylate, Compositions Thereof, and Uses Thereof - (2R)-2-Phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided. | 12-31-2009 |
| 20090076145 | DEUTERIUM-ENRICHED AMIBEGRON - The present application describes deuterium-enriched amibegron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
| 20120196930 | TOPICAL FORMULATION FOR DIABETIC FOOT ULCERS - This invention relates to a new topical gel formulation of the drug Esmolol hydrochloride for treatment of chronic wounds such as diabetic wounds, burn wounds, venous ulcers and pressure ulcers. | 08-02-2012 |
| 20110034552 | LONG-CHAIN OXYAMINOPOLYOL BASED GELATOR AND GEL - [Problems to be Solved] It is an object of the present invention to provide a gelator containing a long chain oxyaminopolyol capable of forming a gel with a small amount thereof over a liquid property range from acidic to alkaline, and a gel having high environmental suitability, biocompatibility and biodegradability. | 02-10-2011 |
| 20110034553 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - A conjugate comprising L-DOPA covalently linked to at least one y-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder. | 02-10-2011 |
| 20120302637 | Methods of Treating Tachycardia and/or Controlling Heart Rate While Minimizing and/or Controlling Hypotension - A method of treating tachycardia while minimizing and/or controlling hypotension associated with such treatment includes administering a therapeutically effective amount of a pharmaceutical composition comprising the S-isomer of esmolol to a subject in need thereof. | 11-29-2012 |
| 20090176878 | GENETIC POLYMORPHISMS AND SUBSTANCE DEPENDENCE - The invention encompasses a method for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene. The invention also encompasses determining the response of a subject to a therapeutic substance, treating substance dependence in a subject, and evaluating the response of a subject to a substance cessation treatment. | 07-09-2009 |
| 20120115948 | INHIBITORS OF ANAPHASE PROMOTING COMPLEX ACTIVITY - The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibing the ubiquitination activity of the APC by administering compositions of the invention. | 05-10-2012 |
| 20090111874 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof - The present invention relates to novel phenyl-N-acyl derivatives of biogenic amines and amino acids of general formula (I) as cyclooxynease inhibitors, possessing analgetic and anti-inflammatory properties and devoid of side effects in particular ulcerogeneity and pro-spasmodic actions, as well as capability to potentiate effect of other analgetics, and possessing in addition antihypoxic, antidepressant and anti-Parkinsonistic action; as well as to the processes for the preparation novel and known phenyl-N-acyl derivatives of biogenic amines, to a pharmaceutical composition and to an agent comprising compounds of general formula (I) as well as to use thereof and a method of treating. | 04-30-2009 |
| 20090018191 | Deuterated Catecholamine Derivatives and Medicaments Comprising Said Compounds - The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders. | 01-15-2009 |
| 20120277309 | METHODS OF CONTROLLING VENOUS IRRITATION ASSOCIATED WITH THE TREATMENT OF A CARDIAC DISORDER - A pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate in a concentration between about 75 mM and about 150 mM, which is substantially free of the R-isomer or pharmaceutically acceptable salt thereof, is provided. A method of treating a cardiac disorder is also provided and includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride, wherein the (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride is present at a concentration between about 75 mM and about 150 mM and wherein the pharmaceutical composition is substantially free of (R)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate or pharmaceutically acceptable salt thereof. | 11-01-2012 |
| 20080221209 | Enantiomers of amino-phenyl-acetic acid octadec-9-(z) enyl ester, their salts and their uses - Disclosed are enantiomers of amino-phenyl-acetic acid octadec-9-(Z)-enyl ester, and salts thereof, including pharmaceutical compositions, uses and a process for the manufacture thereof. | 09-11-2008 |
| 514539000 | Plural separated benzene rings in Z moiety | 14 |
| 20100035988 | Methods for activating PPAR gamma-type receptors - Novel biaromatic compounds having the following structural formula (I): | 02-11-2010 |
| 20110172303 | DEACETYLASE INHIBITORS AND USES THEREOF - The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacetylase inhibitors) and may be useful in the treatment of proliferative diseases such as cancer. In particular, the inventive compounds are HDAC6 inhibitors. The invention also provide synthetic methods for preparing the inventive compounds. | 07-14-2011 |
| 20080306150 | Compounds for the Treatment of Metabolic Disorders - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R is hydrogen, halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; R is alkyl having from 1 to 3 carbon atoms; R | 12-11-2008 |
| 20090163589 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 06-25-2009 |
| 20090170938 | FUNGICIDAL ACTIVE INGREDIENT COMBINATION - Active compound combinations comprising an oxime ether derivative of the formula (I) | 07-02-2009 |
| 20100311829 | Novel Therapeutic Uses of Beta-3 Adrenergic Receptor Agonist Derivatives in Particular to Modulate Apoptosis - The present invention relates to the new therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to inhibit apoptosis and treat and/or prevent apoptosis-related diseases and disorders. | 12-09-2010 |
| 20100331410 | Biaryl Amides - A compound of formula: | 12-30-2010 |
| 20110077299 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION - The present invention relates to a phenylalanine derivative of Formula (I) wherein X | 03-31-2011 |
| 20110263704 | Methods of Using Cycloalkylmethylamines - The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications. | 10-27-2011 |
| 20100029763 | METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES - The present invention refers to new derivatives of the penta-1,4-dien-3-ones, as well as their processes of preparation. These compounds present strong antitumoral activity and promising antiparasitic action, behaving as almost atoxic by laboratory assays and also by hystopathologic studies. The present invention refers also to a pharmaceutical composition including the referred compounds, method of treatment for cancer and parasitic diseases. | 02-04-2010 |
| 20090069421 | CRYSTAL POLYMORPH OF HYDROXYNOREPHEDRIN DERIVATIVE HYDROCHLORIDE - The present invention provides a novel crystal polymorph of ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride which can be determined by characteristic diffraction peaks of the powder X-ray diffraction or the like, and obtained from ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate by a specific method. | 03-12-2009 |
| 20100286268 | TOPICAL COMPOSITION - The invention relates to beneficial topical pharmaceutical compositions comprising the diclofenac diethylammonium salt in unusually high amounts. Said compositions represent opaque emulsion-gels with unique properties such as high skin penetration, no irritation, high stability, complete dissolution of the active and high pain relief. | 11-11-2010 |
| 20110105608 | MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING - Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer. | 05-05-2011 |
| 20080221210 | Thyroid Receptor Agonists - The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor. Formula (I), wherein R | 09-11-2008 |
| 514541000 | Aldehyde or ketone in Z or Y radical | 3 |
| 20100280108 | Antitumoral Compounds - A compound of general formula (I) | 11-04-2010 |
| 20100216881 | Enhydrazone esters for treating asthma, allergy and inflammation - The enhydrazone esters for treating asthma, allergy, and inflammation relate to the use of two cyclohexenone derivatives and pharmaceutically acceptable salts thereof in the treatment of asthma, allergies, and inflammation. The esters have the formula: | 08-26-2010 |
| 20100204321 | Antitussive and Bronchodilator uses for enaminone ester - The antitussive and bronchodilator use for an enaminone ester relates to the use of ethyl 4-[(4-chlorophenyl)amino]-6-methyl-2-oxocyclohex-3-en-1-oate (also referred to as “enaminone E121”) for treatment of respiratory conditions, and particularly to use of the ester as the active ingredient in a cough suppressant for nonproductive cough. The ester may be used to achieve an antitussive effect, a bronchodilator effect, or both in a patient in need thereof. The ester may be formulated in any desired delivery form (such as a tablet, a capsule, a time-release capsule, a syrup, a liquid, an injection, a spray, or an inhalant), and be combined with any suitable pharmaceutical carrier, vehicles, binders, fillers, disintegrators, lubricants, solubilizers, emulsifiers, surfactants, and other excipients. | 08-12-2010 |
| 514542000 | Z radical contains two or more nitrogen atoms at least one of which forms a C(=X)N group (X is chalcogen) | 4 |
| 20090149535 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS - The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): | 06-11-2009 |
| 20110230555 | Enzyme Inhibitors and the Use Thereof - The present invention provides compounds and methods for the treatment of diseases or disorders such as heart failure, hyperlipidemia, hypercholesterolemia, gonadotropin deficiency, diabetes mellitus, metabolic syndrome, hyperglycemia, insulin resistance, glucose intolerance, obesity, psoriasis, atopic dermatitis, and cancer. | 09-22-2011 |
| 20090036528 | Multifunctional and combinational application of aspartame and or futhan - The present invention is an application, composition, and method of using a pharmaceutically effective amount of aspartame or its primary metabolite aspartyl-phenylalanine in systematic and periodic application or dose as an aspirin (NSAID) substitute, treatment for osteoporosis, and or topical treatment for Rosacea. | 02-05-2009 |
| 20120277310 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - A conjugate comprising L-DOPA covalently linked to at least one γ-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder. | 11-01-2012 |
